ROCKVILLE, Md., Feb. 19 Human Genome Sciences,Inc. (Nasdaq: HGSI) today announced that it will sponsor a conference call todiscuss its financial results for the year ended December 31, 2007. Theseresults are expected to be disclosed on Monday, February 25, 2008, after thecapital markets close.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010612/HGSLOGO )
The conference call will be hosted by senior management and will be heldon Monday, February 25, 2008 at 4:30 pm Eastern Time.
Investors may listen to the call by dialing (913) 312-1469 or(888) 221-9588 passcode 4474660, five to 10 minutes before the start of thecall. A replay of the conference call will be available within a few hoursafter the call ends. Investors may listen to the replay by dialing(719) 457-0820 or 888-203-1112 confirmation code 4474660.
This conference call also will be webcast and may be accessed athttp://www.hgsi.com. Investors interested in listening to the live webcastshould log on before the conference call begins in order to download anysoftware required. The archive of the conference call will remain availablefor several days.
The mission of HGS is to apply great science and great medicine to bringinnovative drugs to patients with unmet medical needs.
HGS and Human Genome Sciences are trademarks of Human Genome Sciences,Inc.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended, and Section 21E ofthe Securities Exchange Act of 1934, as amended. The forward-lookingstatements are based on Human Genome Sciences' current intent, belief andexpectations. These statements are not guarantees of future performance andare subject to certain risks and uncertainties that are difficult to predict.Actual results may differ materially from these forward-looking statementsbecause of the Company's unproven business model, its dependence on newtechnologies, the uncertainty and timing of clinical trials, the Company'sability to develop and commercialize products, its dependence on collaboratorsfor services and revenue, its substantial indebtedness and lease obligations,its changing requirements and costs associated with planned facilities andclinical trials, intense competition, the uncertainty of patent andintellectual property protection, the Company's dependence on key managementand key suppliers, the uncertainty of regulation of products, the impact offuture alliances or transactions and other risks described in the Company'sfilings with the Securities and Exchange Commission. In addition, the Companywill continue to face risks related to animal and human testing, to themanufacture of ABthrax and to FDA concurrence that ABthrax meets therequirements of the ABthrax contract. If the Company is unable to meet theproduct requirements associated with the ABthrax contract, the U.S. Governmentwill not be required to reimburse the Company for the costs incurred or topurchase any ABthrax doses. Existing and prospective investors are cautionednot to place undue reliance on these forward-looking statements, which speakonly as of today's date. Human Genome Sciences undertakes no obligation toupdate or revise the information contained in this announcement whether as aresult of new information, future events or circumstances or otherwise.
SOURCE Human Genome Sciences, Inc.